Graham Dixon
Directeur Technique/Scientifique/R&D chez MITHRA PHARMACEUTICALS S.A.
Profil
Graham K.
Dixon's current job(s) include being the Chairman at Apaxen SA, a Director at InteRNA Technologies BV, the Chief Scientific Officer at Mithra Pharmaceuticals SA, and the Head of Research & Development at Zaluvida Holdings Pte Ltd.
Dr. Dixon's former job(s) include being the Chief Executive Officer at Neem Biotech Ltd., the Chairman at HepaRegeniX GmbH from 2017 to 2022, an Independent Director at Alligator Bioscience AB from 2019 to 2024, the Head of Research & Development at AstraZeneca PLC from 1994 to 2002, the Senior Vice President of Drug Discovery at Galapagos NV from 2004 to 2012, the CSO and Head of Research & Development at Valerio Therapeutics SA from 2015 to 2017, the Head of Research & Development at Zeneca Garden Care from 1994 to 2002, the Chief Scientific Officer at Galapagos Genomics NV, the CSO and Head of Research & Development at Addex Therapeutics Ltd., the Chief Scientific Officer at Entomed SA, the Chief Scientific Officer at F2G Ltd.
from 2002 to 2003, and the CSO and Head of Research & Development at Sensorion SA. Dr. Dixon's education history includes an undergraduate degree from the University of Bradford and a doctorate degree from Swansea University.
Postes actifs de Graham Dixon
| Sociétés | Poste | Début |
|---|---|---|
| MITHRA PHARMACEUTICALS S.A. | Directeur Technique/Scientifique/R&D | 01/04/2019 |
InteRNA Technologies BV
 InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | Directeur/Membre du Conseil | - |
Zaluvida Holdings Pte Ltd.
 Zaluvida Holdings Pte Ltd. Other Consumer ServicesConsumer Services Zaluvida Holdings Pte Ltd. provides solutions that improve the lives of livestock and protect the planet. Zaluvida Holdings is based in Singapore, Singapore. The Singaporean company also offers products that help pets stay healthier. The private company's focus is on developing new alternatives to antibiotics that can benefit farmers. and has subsidiaries in Switzerland, Germany, and Malaysia. | Directeur Technique/Scientifique/R&D | - |
Apaxen SA
 Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | Président | 18/07/2022 |
Anciens postes connus de Graham Dixon
| Sociétés | Poste | Fin |
|---|---|---|
| ALLIGATOR BIOSCIENCE AB | Directeur/Membre du Conseil | 07/05/2024 |
HepaRegeniX GmbH
 HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | Président | 30/03/2022 |
| VALERIO THERAPEUTICS | Directeur Technique/Scientifique/R&D | 01/03/2017 |
| GALAPAGOS NV | Directeur Technique/Scientifique/R&D | 14/03/2012 |
Galapagos Genomics NV
 Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Directeur Technique/Scientifique/R&D | 02/05/2008 |
Formation de Graham Dixon
| University of Bradford | Undergraduate Degree |
| Swansea University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 7 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| GALAPAGOS NV | Health Technology |
| VALERIO THERAPEUTICS | Health Technology |
| MITHRA PHARMACEUTICALS S.A. | Health Technology |
| ALLIGATOR BIOSCIENCE AB | Health Technology |
| ADDEX THERAPEUTICS LTD | Health Technology |
| SENSORION | Health Technology |
| Entreprise privées | 9 |
|---|---|
Zeneca Garden Care
 Zeneca Garden Care Pharmaceuticals: OtherHealth Technology Part of AstraZeneca PLC, Zeneca Garden Care is a British company that develops and manufactures pharmaceutical products, agrochemicals, and specialty chemicals. The company is based in Macclesfield, UK. Zeneca Garden Care was acquired by Zeneca Group Plc on January 01, 1995 for $84.16 million. | Health Technology |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Health Technology |
Entomed SA
 Entomed SA Pharmaceuticals: MajorHealth Technology Entomed SA discovers and develops novel medicines derived from insects. It discovers and develops new drugs derived from the biology of insects with a focus on their immune response. Entomed's technology is based on the scientific work carried out by Prof. Jules A. Hoffmann's world leading team in the CNRS Institute of Molecular and Cellular Biology (IBMC) in Strasbourg. The company was founded in 1999 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | Health Technology |
Neem Biotech Ltd.
 Neem Biotech Ltd. Pharmaceuticals: MajorHealth Technology Part of InQpharm Group, Neem Biotech Ltd. is a British biotech company focused on developing groundbreaking ways of defeating big health challenges. The company is based in St. Mellons, UK. Leveraging their unique position in antimicrobial R&D, they have expertise in drug discovery. Neem Biotech was acquired by InQpharm Group on August 09, 2012. | Health Technology |
HepaRegeniX GmbH
HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | Commercial Services |
Zaluvida Holdings Pte Ltd.
Zaluvida Holdings Pte Ltd. Other Consumer ServicesConsumer Services Zaluvida Holdings Pte Ltd. provides solutions that improve the lives of livestock and protect the planet. Zaluvida Holdings is based in Singapore, Singapore. The Singaporean company also offers products that help pets stay healthier. The private company's focus is on developing new alternatives to antibiotics that can benefit farmers. and has subsidiaries in Switzerland, Germany, and Malaysia. | Consumer Services |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | Health Technology |
